Nanobiotix’s (EPA:NANO) flagship tumour treatment may also have potential as a cancer vaccine, the company revealed at a leading immuno-therapy conference over the weekend.
In one of three experiments carried out in collaboration with Thomas Jefferson hospital in Chicago, results suggested NBTXR3 actively stimulates the host immune system to attack tumour cells.
Elsa Borghi, Nanobiotix’s chief medical officer, said the research suggests NBTXR3 may be able to transform a tumour into an in situ vaccine by provoking an immune response and thus encouraging the body to attack other similar tumour cells.
This would overcome one of the main barriers to the use of immuno-therapy as a cancer treatmen, she said, namely that most tumours do not provoke an immune response, which renders immunotherapy ineffective in many patients.
A cancer vaccine would be a hugely significant departure for NBTXR3, as its development so far has been into the potential as an adjunct to radiotherapy.
Here, NBTXR3 nanoparticles are directly injected into cancerous tumours where they absorb the ionizing radiation delivered by radiotherapy and magnify its effect locally.
This shrinks the tumour making it easier to remove during surgery.
Two additional experiments at Thomas Jefferson indicated radiotherapy with NBTXR3 elicited a marked enhancement of Immunogenic Cell Death (ICD) compared to radiotherapy alone.
A second experiment into abscopal effects, meanwhile, showed that the NBTXR3 /radiotherapy combination meant a statistically significant increase in overall survival.
Laurent Levy, Nanobiotix’s chief executive, added: “These exciting data show that NBTXR3 could be a potential game changer in Immuno-oncology combination landscape.
“This raises the possibility of synergies between NBTXR3, radiotherapy and immunotherapies.
“On the top of existing core developments of our product as a single agent, this is opening new doors for industrial collaborations.”
Nanobiotix presented the data at the 31 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), in Maryland.
Story by ProactiveInvestors